SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001753926-22-000545
Filing Date
2022-04-18
Accepted
2022-04-18 16:21:27
Documents
2
Group Members
AMIN NATHOOANSON ADVISORS INC.ANSON MANAGEMENT GP LLCBRUCE R. WINSONMOEZ KASSAM

Document Format Files

Seq Description Document Type Size
1 SC 13D/A g082975_13d.htm SC 13D/A 119911
2 EXHIBIT 99.1 g082975_ex99-1.htm EX-99.1 33722
  Complete submission text file 0001753926-22-000545.txt   155738
Mailing Address 655 MONTGOMERY STREET SUITE 900 SAN FRANCISCO CA 94111
Business Address 655 MONTGOMERY STREET SUITE 900 SAN FRANCISCO CA 94111 (408) 737-2734
Amarantus Bioscience Holdings, Inc. (Subject) CIK: 0001424812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87050 | Film No.: 22832363
SIC: 2834 Pharmaceutical Preparations

Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

IRS No.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SC 13D/A